Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B
Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B have?
Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B has 56 citations in the OpenAlex counts ScholarIQ stores.
When was Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B published?
Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B has 2020 year in the ScholarIQ index.
What is the open-access status of Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B?
Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B has closed oa status in the ScholarIQ index.
What is the DOI of Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B?
The DOI for Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B is on the source record.
What is the PMID of Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B?
The PMID for Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B is on the source record.
What is the OpenAlex record for Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B?
The OpenAlex for Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B is on the source record.